Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT01413308` - Pulmonary Functions Test in Patients After Fontan Operation	N/A
Completed	`NCT02269709` - Stage 3 Fontan Operation Liver Ultrasound Study	N/A
Recruiting	`NCT02414321` - The Role of the Pulmonary Vasculature in the Fontan Circulation

See also

Status

Clinical Trial

Phase

Enrolling by invitation

NCT01413308 - Pulmonary Functions Test in Patients After Fontan Operation

N/A

Completed

NCT02269709 - Stage 3 Fontan Operation Liver Ultrasound Study

N/A

Recruiting

NCT02414321 - The Role of the Pulmonary Vasculature in the Fontan Circulation

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT05474664
Study type	Interventional
Source	Seoul National University Hospital
Contact	Gi Beom Kim
Phone	+82220720266
Email	ped9526@snu.ac.kr
Status	Not yet recruiting
Phase	Phase 2
Start date	August 1, 2022
Completion date	October 31, 2024

Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms